PASADENA, Calif. --(BUSINESS WIRE)--May 18, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Janssen Pharmaceuticals, Inc. , (Janssen) part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has delivered written notice of its intent to exercise its option right
PASADENA, Calif. --(BUSINESS WIRE)--May 12, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2021 RBC Capital Markets Global Healthcare – May 18-20, 2021 May 18, 2021 , 11:30 a.m.
Conference Call and Webcast Today, May 4, 2021 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--May 4, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2021 . The company is hosting a conference call today, May
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 28, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim 48-week liver biopsy results from the AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation investigational RNA
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 16, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 4, 2021 , at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2021 .
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 1, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ARO-APOC3, the company’s investigational RNA interference (RNAi)
Conference Call and Webcast Today, February 4 at 4:30 p.m. EST PASADENA, Calif. --(BUSINESS WIRE)--Feb. 4, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2020 . The company is hosting a conference call at 4:30
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 25, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2b dose-finding clinical study of ARO-ANG3, the company’s
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 19, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 4, 2021 , at 4:30 p.m. EST to discuss its financial results for the fiscal first quarter ended December 31, 2020 .